Médicaments génériques : pivot de la reconstruction de l’industrie pharmaceutique
The pharma has a particular significance given the challenges it involves for public health, economics, politics and ethics. The medicines production is therefore subject to multiple and complex regulations, both national and international. While some of these regulations was designed against major...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association Recherche & Régulation
2015-06-01
|
| Series: | Revue de la Régulation |
| Subjects: | |
| Online Access: | https://journals.openedition.org/regulation/11143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832577973437333504 |
|---|---|
| author | Philippe Abecassis Nathalie Coutinet |
| author_facet | Philippe Abecassis Nathalie Coutinet |
| author_sort | Philippe Abecassis |
| collection | DOAJ |
| description | The pharma has a particular significance given the challenges it involves for public health, economics, politics and ethics. The medicines production is therefore subject to multiple and complex regulations, both national and international. While some of these regulations was designed against major pharmaceutical companies (Big Pharma), firms have often co-constructed the regulation with the intent to take advantage. The analysis of the changing patterns of production and successive big pharma’s strategies can highlight the importance of the co-construction of regulation. This work shows how the “generic” model of medicines production which follows the “blockbusters” model appears as a transitional model, a pivot from which firms intend to escape as quick as possible, encouraged by the regulators, to find a “custombusters” model without its predecessor’s defects. |
| format | Article |
| id | doaj-art-930d69776c6a4cad91b9c809a4b49bea |
| institution | Kabale University |
| issn | 1957-7796 |
| language | English |
| publishDate | 2015-06-01 |
| publisher | Association Recherche & Régulation |
| record_format | Article |
| series | Revue de la Régulation |
| spelling | doaj-art-930d69776c6a4cad91b9c809a4b49bea2025-01-30T14:26:06ZengAssociation Recherche & RégulationRevue de la Régulation1957-77962015-06-011710.4000/regulation.11143Médicaments génériques : pivot de la reconstruction de l’industrie pharmaceutiquePhilippe AbecassisNathalie CoutinetThe pharma has a particular significance given the challenges it involves for public health, economics, politics and ethics. The medicines production is therefore subject to multiple and complex regulations, both national and international. While some of these regulations was designed against major pharmaceutical companies (Big Pharma), firms have often co-constructed the regulation with the intent to take advantage. The analysis of the changing patterns of production and successive big pharma’s strategies can highlight the importance of the co-construction of regulation. This work shows how the “generic” model of medicines production which follows the “blockbusters” model appears as a transitional model, a pivot from which firms intend to escape as quick as possible, encouraged by the regulators, to find a “custombusters” model without its predecessor’s defects.https://journals.openedition.org/regulation/11143health policypharmaceutical industrydrug market regulationgenericsbig pharma |
| spellingShingle | Philippe Abecassis Nathalie Coutinet Médicaments génériques : pivot de la reconstruction de l’industrie pharmaceutique Revue de la Régulation health policy pharmaceutical industry drug market regulation generics big pharma |
| title | Médicaments génériques : pivot de la reconstruction de l’industrie pharmaceutique |
| title_full | Médicaments génériques : pivot de la reconstruction de l’industrie pharmaceutique |
| title_fullStr | Médicaments génériques : pivot de la reconstruction de l’industrie pharmaceutique |
| title_full_unstemmed | Médicaments génériques : pivot de la reconstruction de l’industrie pharmaceutique |
| title_short | Médicaments génériques : pivot de la reconstruction de l’industrie pharmaceutique |
| title_sort | medicaments generiques pivot de la reconstruction de l industrie pharmaceutique |
| topic | health policy pharmaceutical industry drug market regulation generics big pharma |
| url | https://journals.openedition.org/regulation/11143 |
| work_keys_str_mv | AT philippeabecassis medicamentsgeneriquespivotdelareconstructiondelindustriepharmaceutique AT nathaliecoutinet medicamentsgeneriquespivotdelareconstructiondelindustriepharmaceutique |